BRADYKININ acts as a powerful vasodilator upon the systemic circulation.'-10 Contradictory reports, however, have been published concerning its effect on the pulmonary vascular bed. In different studies carried out in various animal species, the drug has been reported as eliciting either dilatation7' 11 or constriction12 of the pulmonary vessels.
Gersmeyer and Spitzbarth6 observed a rise in pulmonary arterial pressure when a single dose of bradykinin was intravenously injected into intact man. In an earlier publication from this laboratory, a decrease in pulmonary vascular resistance was noted in eight of 10 patients with normal pulmonary vascular pressures receiving a continuous intravenous infusion of synthetic bradykinin. 8 Since a functional component of vasoconstriction is admitted in most cases of pulmonary hypertension,13' 14 patients with high pulmonary vascular pressures may serve, within certain limits, as a suitable material for assessing the action of a vasodilator agent on the lesser circulation.
The aim of the present investigation was to evaluate the hemodynamic alterations observed in patients with pulmonary hypertension secondary to rheumatic heart disease during the intravenous administration of bradykinin.
Method
Of the 21 patients studied, 10 fig. 1) . Likewise, when the per cent increments in the flow through the mitral valve were correlated with the per cent increments in mean left atrial pressure, in the 15 patients with pure mitral stenosis, a significant coefficient (r = + 0.747, P < 0.01) was encountered ( fig. 1 ). In contrast, the correlation coefficient computed from the comparison of the changes in cardiac output with the changes in mean pulmonary arterial pressure was very low and not significant (r= + 0.322). These findings may well be explained by the relatively fixed resistance represented by the ostium of the stenotic mitral valve, which would require for a rise in flow through it a proportional increase of the left atrioventricular filling pressure gradient and, consequently, of the pulmonary venous-left atrial pressure. The same would not occur with the pulmonary arteriovenous pressure gradient and the pulmonary arterial pressure, the changes in which would be related to the changes in diameter of the small pulmonary vessels, responsible for the major portion of the pulmonary vascular resistance. Since this resistance is essentially variable both by passive (mechanical) and active modifications in the caliber of the vessels, the amount of variation would depend largely on the degree of structural and functional alterations of the vascular walls present in each case. During bradykinin infusion, the pulmonary vascular resistance fell in 19 of the 21 cases studied (mean change,-22%). Since the transmural pressure in the pulmonary vascular bed, as evaluated from the average intravascular pressure, rose in all patients ( + 25%), the fall in resistance could be attributed to a passive distention of the small pulmonary vessels. The diverse degree of structural and functional alterations of the vascular walls in the different patients, as mentioned before, was probably the main reason for the observed failure of the individual increases in average intravascular pressure to correlate with the corresponding decreases in pulmonary vascular resistance (r + 0.199).
In most patients with pure mitral stenosis, no appreciable modifications of the pulmonary blood volume was noted while bradykinin was being injected, in spite of the important rise of the pulmonary intravascular pressures. This fact leads to the conclusion that the pulmonary vascular system behaved as a compartment of low distensibility,16 during the action of bradykinin. This conclusion is only valid for the pulmonary vascular bed as a whole (left atrium included), since the method employed to measure the pulmonary blood volume was not designed to detect different changes in volume or eventual shifts of blood from one to another of the various pulmonary vascular segments.16
As could be expected from experiments carried out in intact animals or man, the modifications in resistance and capacity observed in the pulmonary vascular bed must have represented the net effect of passive response due to changes in transmural pressure and active variations in pulmonary vascular distensibility. 16 action of bradykinin on the systemic vessels and heart rather than a direct effect of the drug on the pulmonary vessels.
